- Current Price: ~$62.8 per share (Oct. 16, 2025), up about +7% on the day [1]. Over the past week HIMS is roughly unchanged (~–1%), and about +5% above its level one month ago [2].
- Year-to-Date Rally: Shares have more than doubled in 2025. HIMS is up roughly +110–115% year-to-date [3] [4], far outpacing the broader telehealth sector.
- Recent News: The stock jumped ~12–16% on Oct. 15 after Hims & Hers announced a new perimenopause/menopause care program [5]. Earlier in September, Hims expanded into men’s health by rolling out low-testosterone treatment plans [6].
- Regulatory Scrutiny: In mid-September, the FDA publicly criticized Hims for a Super Bowl ad and sent warning letters about its weight-loss drug promotions [7] [8]. The FTC is also probing Hims’ advertising and subscription practices [9]. Such headlines have triggered sell-offs – the stock slipped ~6–7% after the FDA letters and ~5% on the FTC news [10].
- Analyst Sentiment: Wall Street is divided. The consensus is mostly “Hold/Reduce” [11] [12]. For example, Bank of America analyst Allen Lutz reiterated a Sell rating with a $28 price target (implying ~55% downside) despite the enthusiasm over women’s health [13]. On average, analysts’ 12-month targets cluster in the high-$30s (around $39 on MarketBeat) [14].
- Performance vs. Peers: HIMS has vastly outperformed traditional telehealth peers. For instance, HIMS is up ~158% in 2025, whereas long-time rival Teladoc (TDOC) is down ~44% [15].
Figure: Hims & Hers markets a broad telehealth platform for men’s and women’s health [16]. Its stock has surged with the boom in telehealth and weight-loss treatments.
Women’s Health Expansion Sparks Rally
On Oct. 15, Hims & Hers stunned the market by launching a dedicated menopause/perimenopause care program on its “Hers” telehealth platform. The company said the new service would connect women with personalized hormone therapies (estradiol, progesterone, etc.) to ease symptoms like hot flashes and sleep issues [17]. This push into a historically underserved sector (roughly 1.3 million U.S. women enter menopause each year) met eager investor demand. As Benzinga and TS2.tech reported, HIMS stock raced +10–13% that day, trading near $60 with extremely heavy volume (about 29 million shares, ~15× the daily average) [18]. By the close, HIMS was up roughly +16%, a one-day gain not seen in months [19] [20].
This women’s health launch is just the latest growth initiative. Hims’ CEO Andrew Dudum had hinted earlier that 2025 would be an “exciting period of growth” with new “high-impact specialties” [21]. Indeed, the company is aggressively broadening beyond its core prescription offerings. In the past year it moved strongly into weight-loss (selling compounded semaglutide prescriptions when branded Wegovy/Ozempic were scarce [22]) and more recently rolled out prescription plans for low testosterone in September [23] [24]. (Its partner Novo Nordisk has even allowed HIMS to dispense Wegovy through a “NovoCare Pharmacy” link, although that tie-up ended mid-2025 [25].) On Oct. 15’s announcement, Hims noted its goal is to drive the “Hers” platform from ~500,000 subscribers now to over $1 billion in annual revenue by 2026 [26] [27].
Regulatory Headwinds Amid GlP-1 Hype
Despite the bullish growth narrative, Hims has faced regulatory headwinds this fall. In mid-September the FDA publicly condemned a Hims & Hers Super Bowl commercial for touting the benefits of GLP-1 weight-loss drugs without listing risks [28] [29]. Soon after, the FDA issued warning letters to Hims and other telehealth companies, accusing them of making unapproved “copies” of the drugs and misinforming consumers [30] [31]. Shortly before that, Bloomberg News reported the FTC was probing Hims over its marketing and subscription cancellation practices [32].
These developments spooked investors. TS2.tech notes that HIMS stock fell about 6–7% after the FDA warning letters and ~5% when the FTC news broke [33]. (In fact, after-hours trading on Sept. 14 saw a ~7% slide [34].) In the Simply Wall St report dated Oct. 15, analysts noted that short-term headline risk from the FDA/FTC kept some traders cautious, with the stock dipping ~6.8% over the prior week on the news [35].
Stock Performance & Outlook
Figure: The Hims & Hers logo. The telehealth stock has “skyrocketed” this year, fueled by weight-loss medication demand and new service expansions [36] [37].
Hims & Hers is now a mid-cap of roughly $13–14 billion. Trading around $62.8 on Oct. 16 [38], it has shown tremendous volatility. According to a TradingView summary, HIMS is up +7.0% in the past 24 hours and +5.1% over the last 30 days [39] [40]. Year-over-year, shares have gained over +200% [41] (Simpy Wall St quotes a +114% gain since January [42]). The all-time high is about $72.98 (Feb 2025) [43], so the stock still sits roughly ~19% below that peak [44].
Wall Street will be watching the upcoming Q3 earnings (expected Nov 3 after market close). Market analysts expect continued strength: a Canaccord note cited by TS2 forecasts “high growth fueled by weight-loss and women’s health offerings” [45]. Key metrics to watch are subscriber growth and margins. (In Q2 2025, Hims grew subscribers ~31% YoY to 2.44 million [46], but gross margins dipped as it shifted to custom compounded GLP-1 plans [47].) TS2 also highlights that management reiterated 2025 guidance of roughly $2.35B in revenue with ~11.5% EBITDA margin [48], suggesting confidence in the ramp-up.
However, the company’s lofty valuation means even small execution gaps could unsettle investors. In technical terms, the stock is well above its 50-day moving average (as of Oct. 15) and approaching peak levels [49], which often leads to “choppy action” [50]. Some strategists expect pullbacks if subscriber growth or acquisition costs disappoint. In the short run, analysts caution volatility; in the long run, many remain intrigued by the growth story. One bullish note even speculated HIMS could reach the $100s if it sustains ~30% revenue growth into 2026 [51].
Analyst Ratings & Commentary
Analysts’ views on HIMS are polarized. TipRanks and MarketBeat data show a consensus “Hold/Reduce” bias [52] [53]. Of 14 analysts tracked on MarketBeat, only 2 rate the stock a Buy (and 9 Hold, 3 Sell), implying a “Reduce” consensus [54] [55]. Price targets vary wildly: some bearish forecasters have targets in the $26–30 range, while bulls set targets into the $65–68 zone [56].
A prominent skeptic is Allen Lutz of Bank of America (4-star). Lutz reiterated his Sell rating on Oct. 16, keeping a $28 target [57]. He noted the women’s health launch broadens the brand, but still expects only modest near-term revenue contribution from it, with payoff into 2026 [58]. Lutz’s criticisms include rising customer acquisition costs, competition, and the impact of recent FDA/FTC reforms on margins [59]. Conversely, some others are more positive. For example, Canaccord Genuity has rated HIMS a Buy and even lifted its target to $68 in September [60], citing the company’s rapid specialty expansion and strong user engagement.
Independent analyses echo this split. Simply Wall St’s Oct. 15 report calls HIMS “skyrocketing” (+114% YTD) but notes a 6.8% dip last week after negative headlines [61] [62]. Its discounted cash flow model pegs fair value around $62.47, implying the current price is actually about 13.5% below intrinsic value [63]. In other words, on cash-flow fundamentals the stock might be undervalued. However, its forward P/E (~63x) is extremely rich — roughly in line with its own “fair” P/E of 64x but far above sector norms [64].
Macro/Industry Context and Outlook
Broader sector forces are a big part of Hims & Hers’ story. The telehealth and consumer health market has been booming, especially with the explosion of obesity drugs. HIMS has carved out a strong niche: a direct-to-consumer subscription model covering men’s wellness (sexual health, hair, skin) and women’s specialties (dermatology, menopause, fertility) [65] [66]. By contrast, older peers like Teladoc focus more on employer contracts. This focus has paid off: Zacks and TS2 highlight that HIMS’s diversified D2C platform (with over 2.4M subs) is more “capital-efficient” than competitors, earning a Zacks “Rank #2 (Buy)” rating [67].
Drugmakers are noticing too: for example, Novo Nordisk agreed last year to have HIMS distribute branded Wegovy to its customers [68]. The recent FDA clampdown on weight-loss marketing is partly a result of HIMS helping to democratize access to these treatments (and partly due to regulatory caution). On the macro side, overall interest-rate pressures and market sentiment for growth stocks will influence HIMS. In a higher-rate environment, richly valued tech/health names can swing with market tides. But the specific GLP-1 tailwinds (ongoing demand, new drug approvals) may insulate HIMS relative to other growth stocks.
In sum, Hims & Hers is a high-volatility story riding powerful industry trends. The recent women’s health expansion could be a major catalyst if it brings in new subscribers as hoped. But investors will be weighing that against mixed analyst ratings and regulatory uncertainties. The coming quarters (and especially subscriber and margin figures in Q3 results) will be telling. For now, the company’s ambitious growth strategy – and its gamble on weight-loss drug demand – have kept HIMS in the spotlight, as emphasized by TS2 and other analysts [69] [70].
Sources: Latest stock data and consensus ratings [71] [72] [73]; company press releases and TS2.tech analysis [74] [75]; Reuters and Benzinga reports on regulatory news [76] [77]; Simply Wall St valuation data [78] [79]; and TipRanks/MarketBeat coverage of analyst calls [80] [81]. (See text for full citations.)
References
1. www.tradingview.com, 2. www.tradingview.com, 3. ts2.tech, 4. simplywall.st, 5. ts2.tech, 6. www.reuters.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.reuters.com, 10. ts2.tech, 11. ts2.tech, 12. www.tipranks.com, 13. www.tipranks.com, 14. ts2.tech, 15. ts2.tech, 16. ts2.tech, 17. ts2.tech, 18. ts2.tech, 19. ts2.tech, 20. ts2.tech, 21. ts2.tech, 22. ts2.tech, 23. ts2.tech, 24. www.reuters.com, 25. ts2.tech, 26. ts2.tech, 27. ts2.tech, 28. www.reuters.com, 29. ts2.tech, 30. www.reuters.com, 31. ts2.tech, 32. www.reuters.com, 33. ts2.tech, 34. www.reuters.com, 35. simplywall.st, 36. simplywall.st, 37. ts2.tech, 38. www.tradingview.com, 39. www.tradingview.com, 40. www.tradingview.com, 41. www.tradingview.com, 42. simplywall.st, 43. www.tradingview.com, 44. ts2.tech, 45. ts2.tech, 46. ts2.tech, 47. ts2.tech, 48. ts2.tech, 49. ts2.tech, 50. ts2.tech, 51. ts2.tech, 52. ts2.tech, 53. www.tipranks.com, 54. ts2.tech, 55. www.tipranks.com, 56. ts2.tech, 57. www.tipranks.com, 58. www.tipranks.com, 59. www.tipranks.com, 60. ts2.tech, 61. simplywall.st, 62. simplywall.st, 63. simplywall.st, 64. simplywall.st, 65. ts2.tech, 66. ts2.tech, 67. ts2.tech, 68. ts2.tech, 69. ts2.tech, 70. ts2.tech, 71. www.tradingview.com, 72. www.tipranks.com, 73. ts2.tech, 74. ts2.tech, 75. ts2.tech, 76. www.reuters.com, 77. www.reuters.com, 78. simplywall.st, 79. simplywall.st, 80. www.tipranks.com, 81. ts2.tech
